Skip to content

EyePoint, Inc. EYPT Additional Paid-In Capital

Additional Paid-In Capital at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$14.4B+9.2%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.83B+49.6%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$1.73B+15.6%
HRO
HarrowHROW
$212.8M-5.7%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$1.16B+0.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$4.48B+5.4%

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+189%
Enterprise value$1.15B+228%
P/S158.5×+151×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's additional paid-in capital?
EyePoint, Inc. (EYPT) reported additional paid-in capital of $1.42B in Q1 2026.
How has EyePoint, Inc. 's additional paid-in capital changed year-over-year?
EyePoint, Inc. 's additional paid-in capital increased by 16.8% year-over-year, from $1.22B to $1.42B.
What is the long-term trend for EyePoint, Inc. 's additional paid-in capital?
Over 5 years (2020 to 2025), EyePoint, Inc. 's additional paid-in capital has grown at a 21.7% compound annual growth rate (CAGR), from $528.36M to $1.41B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.